Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors

NCT04577963 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT04577963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04577963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Lead sponsor
Hutchmed
Phase
Phase 1/2
Overall status
Terminated
Start date
August 9, 2021
Completion date
June 18, 2024
Enrollment
52 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, endometrial cancer, solid tumor, unspecified, adult, triple negative breast cancer